A Phase 2 interventional study of Relatlimab + Nivolumab and Nivolumab in Gastric Cancer, Cancer of the Stomach and Stomach Cancer, sponsored by Bristol-Myers Squibb. Withdrawn at 84 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-19.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing nivolumab in Stomach Neoplasms — 6 open to participants now, 13 under way, 2 of them phase 3. Nivolumab · Stomach Neoplasms.
Among the 30 studies testing nivolumab in Stomach Neoplasms, this one is the 30th largest by enrollment, is one of 4 that started in 2019, is one of 14 in phase 2, and was the 12th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →6 of the 30 studies testing nivolumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–80
Wu Jun · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18–75
Kidney Cancer Research Bureau · Sites in United States
Ages 18+
Fudan University · Sites in China
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 20 · Phase 3 7
First in 2014; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 49 across the 30 interventional studies. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 30 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
14 studies in Stomach Neoplasms by Bristol-Myers Squibb: 1 open now, 4 under way, 1 of them phase 3. Of 9 finished, 3 (33%) have results posted.
Among the 14 studies in Stomach Neoplasms by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 8th registered.
Bristol-Myers Squibb’s Stomach Neoplasms studies by the year they started, since 2001.
4 of the studies testing nivolumab in Stomach Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04997837Phase 3Fudan UniversityStudy of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma | 2027-07-21 |
| NCT03776487M.D. Anderson Cancer CenterNivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | 2026-12-30 |
| NCT03044613Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer | 2027-03 |
| NCT05802056Mayo ClinicAldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis | 2027-04-24 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing nivolumab in Stomach Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 14 in Stomach Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Relatlimab + Nivolumab · Biological: Nivolumab · Drug: Paclitaxel
Biological: Nivolumab · Drug: Paclitaxel
Standard-of-care
Drug: Paclitaxel · Drug: Ramucirumab
Biological: Relatlimab + Nivolumab · Biological: Nivolumab
Standard-of-care
Biological: Nivolumab
Biological: Relatlimab + Nivolumab · Biological: Nivolumab
Drug pages: Relatlimab · Nivolumab
Specified dose on specified days
Also known as: BMS-986213
Specified dose on specified days
Also known as: Opdivo
Specified dose on specified days
Also known as: Taxol, Onxal
Specified dose on specified days
Also known as: Cyramza
Overall response rate (ORR)
Time frame: Approximately 31 months
Incidence of adverse events (AEs)
Time frame: Approximately 5 years
Incidence of serious adverse events (SAEs)
Time frame: Approximately 5 years
Incidence of AEs leading to discontinuation
Time frame: Approximately 5 years
Incidence of deaths
Time frame: Approximately 5 years
Incidence of laboratory abnormalities
Time frame: Approximately 5 years
ORR
Cohort A1
Time frame: Approximately 5 years
Duration of response (DOR)
Time frame: Approximately 5 years
Progression free survival (PFS)
Time frame: Approximately 5 years
Overall survival (OS)
Time frame: Approximately 5 years
Plan to share: Yes — Individual patient level data from this study may be shared with qualified researchers, upon request, following the timelines and process detailed on https://www.bms.com/researchers-and-partners/independent-research/data-sharing-request-process.html
Start is estimated for Oct 2019; primary completion for Feb 2022, 27 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relatlimab · Nivolumab · Paclitaxel